Clinical trial · Observational
An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)
An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study)
NCT01392729CI-TRIAL-00024598completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with interferon alpha 2a in patients with previously untreated metastatic renal cell cancer. Data will be collected from each patient for up to 4 years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- approximately 4 years
Secondary outcomes (3)
- measure
- Overall survival
- timeFrame
- approximately 4 years
- measure
- Response rate
- timeFrame
- approximately 4 years
- measure
- Safety: Incidence of adverse events
- timeFrame
- approximately 4 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically confirmed metastatic renal cell cancer, clear cell type * Eligible for treatment with Avastin and interferon alpha 2a according to local prescribing information Exclusion Criteria: * Contraindications for Avastin or interferon alpha 2a treatment according to local Summary of Product Characteristics * Known hypersensitivity to Avastin and/or interferon alpha 2a or any of its excipients
References
Publications (0)
Data not yet available
No reference posted for this study.